252 related articles for article (PubMed ID: 10505028)
21. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
[TBL] [Abstract][Full Text] [Related]
22. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
Ganguly T; Dhulipala R; Godmilow L; Ganguly A
Hum Genet; 1998 May; 102(5):549-56. PubMed ID: 9654203
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
24. Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.
Vaziri SA; Krumroy LM; Rostai M; Casey G
Hum Mutat; 2001; 17(1):74. PubMed ID: 11139249
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
26. BRCA2 germline mutations in male breast cancer cases and breast cancer families.
Couch FJ; Farid LM; DeShano ML; Tavtigian SV; Calzone K; Campeau L; Peng Y; Bogden B; Chen Q; Neuhausen S; Shattuck-Eidens D; Godwin AK; Daly M; Radford DM; Sedlacek S; Rommens J; Simard J; Garber J; Merajver S; Weber BL
Nat Genet; 1996 May; 13(1):123-5. PubMed ID: 8673091
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil.
Esteves VF; Thuler LC; Amêndola LC; Koifman RJ; Koifman S; Frankel PP; Vieira RJ;
Braz J Med Biol Res; 2009 May; 42(5):453-7. PubMed ID: 19377795
[TBL] [Abstract][Full Text] [Related]
28. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.
Gayther SA; Russell P; Harrington P; Antoniou AC; Easton DF; Ponder BA
Am J Hum Genet; 1999 Oct; 65(4):1021-9. PubMed ID: 10486320
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
[TBL] [Abstract][Full Text] [Related]
30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 mutation analysis in 86 early onset breast/ovarian cancer patients.
Garvin AM; Attenhofer-Haner M; Scott RJ
J Med Genet; 1997 Dec; 34(12):990-5. PubMed ID: 9429140
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
33. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
van Der Looij M; Wysocka B; Brozek I; Jassem J; Limon J; Olah E
Hum Mutat; 2000 May; 15(5):480-1. PubMed ID: 10790213
[TBL] [Abstract][Full Text] [Related]
34. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
35. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
[TBL] [Abstract][Full Text] [Related]
36. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
37. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.
Johannsson O; Loman N; Möller T; Kristoffersson U; Borg A; Olsson H
Eur J Cancer; 1999 Aug; 35(8):1248-57. PubMed ID: 10615237
[TBL] [Abstract][Full Text] [Related]
38. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
39. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer.
Sibille-Hoang C; Froment O; Joos de ter Beerst A; Lepiece V; Huberlant G; Blauwaert G; Vindevoghel A; Canon JL; Gillerot Y
Eur J Cancer Prev; 1998 Feb; 7 Suppl 1():S3-5. PubMed ID: 10866028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
